Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome.

Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C; SEISMIC Study Investigators..

J Clin Endocrinol Metab. 2012 Jun;97(6):2039-49. doi: 10.1210/jc.2011-3350.

PMID:
22466348
2.

Global clinical response in Cushing's syndrome patients treated with mifepristone.

Katznelson L, Loriaux DL, Feldman D, Braunstein GD, Schteingart DE, Gross C.

Clin Endocrinol (Oxf). 2014 Apr;80(4):562-9. doi: 10.1111/cen.12332.

3.

Mifepristone for management of Cushing's syndrome.

Morgan FH, Laufgraben MJ.

Pharmacotherapy. 2013 Mar;33(3):319-29. doi: 10.1002/phar.1202. Review.

PMID:
23436494
4.

A new therapeutic approach in the medical treatment of Cushing's syndrome: glucocorticoid receptor blockade with mifepristone.

Fleseriu M, Molitch ME, Gross C, Schteingart DE, Vaughan TB 3rd, Biller BM.

Endocr Pract. 2013 Mar-Apr;19(2):313-26. doi: 10.4158/EP12149.RA. Review.

PMID:
23337135
5.

Sustained weight loss in patients treated with mifepristone for Cushing's syndrome: a follow-up analysis of the SEISMIC study and long-term extension.

Fein HG, Vaughan TB 3rd, Kushner H, Cram D, Nguyen D.

BMC Endocr Disord. 2015 Oct 27;15:63. doi: 10.1186/s12902-015-0059-5.

6.

The use of the glucocorticoid receptor antagonist mifepristone in Cushing's syndrome.

Castinetti F, Brue T, Conte-Devolx B.

Curr Opin Endocrinol Diabetes Obes. 2012 Aug;19(4):295-9. doi: 10.1097/MED.0b013e32835430bf. Review.

PMID:
22543346
7.

Changes in plasma ACTH levels and corticotroph tumor size in patients with Cushing's disease during long-term treatment with the glucocorticoid receptor antagonist mifepristone.

Fleseriu M, Findling JW, Koch CA, Schlaffer SM, Buchfelder M, Gross C.

J Clin Endocrinol Metab. 2014 Oct;99(10):3718-27. doi: 10.1210/jc.2014-1843.

8.

Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.

Pessina AC, Ciccariello L, Perrone F, Stoico V, Gussoni G, Scotti A, Muggeo M.

Nutr Metab Cardiovasc Dis. 2006 Mar;16(2):137-47.

PMID:
16487914
9.

Mifepristone: treatment of Cushing's syndrome.

Sartor O, Cutler GB Jr.

Clin Obstet Gynecol. 1996 Jun;39(2):506-10. Review.

PMID:
8734015
10.

The use of mifepristone in the treatment of Cushing's syndrome.

Carroll T, Findling JW.

Drugs Today (Barc). 2012 Aug;48(8):509-18. doi: 10.1358/dot.2012.48.8.1841299.

PMID:
22916338
11.

ASSOCIATION BETWEEN MIFEPRISTONE DOSE, EFFICACY, AND TOLERABILITY IN PATIENTS WITH CUSHING SYNDROME.

Yuen KC, Williams G, Kushner H, Nguyen D.

Endocr Pract. 2015 Oct;21(10):1087-92. doi: 10.4158/EP15760.OR. Erratum in: Endocr Pract. 2015 Dec;21(12):1449.

PMID:
26121447
12.

Medical treatment of Cushing's syndrome: glucocorticoid receptor antagonists and mifepristone.

Castinetti F, Conte-Devolx B, Brue T.

Neuroendocrinology. 2010;92 Suppl 1:125-30. doi: 10.1159/000314224.

PMID:
20829633
13.

Is diabetes in Cushing's syndrome only a consequence of hypercortisolism?

Giordano C, Guarnotta V, Pivonello R, Amato MC, Simeoli C, Ciresi A, Cozzolino A, Colao A.

Eur J Endocrinol. 2013 Dec 21;170(2):311-9. doi: 10.1530/EJE-13-0754.

15.

Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study.

Mahfoud F, Schlaich M, Kindermann I, Ukena C, Cremers B, Brandt MC, Hoppe UC, Vonend O, Rump LC, Sobotka PA, Krum H, Esler M, Böhm M.

Circulation. 2011 May 10;123(18):1940-6. doi: 10.1161/CIRCULATIONAHA.110.991869.

16.

Effects of a combination of recombinant human growth hormone with metformin on glucose metabolism and body composition in patients with metabolic syndrome.

Herrmann BL, Berg C, Vogel E, Nowak T, Renzing-Koehler K, Mann K, Saller B.

Horm Metab Res. 2004 Jan;36(1):54-61.

PMID:
14983408
18.

Merits and pitfalls of mifepristone in Cushing's syndrome.

Castinetti F, Fassnacht M, Johanssen S, Terzolo M, Bouchard P, Chanson P, Do Cao C, Morange I, Picó A, Ouzounian S, Young J, Hahner S, Brue T, Allolio B, Conte-Devolx B.

Eur J Endocrinol. 2009 Jun;160(6):1003-10. doi: 10.1530/EJE-09-0098.

19.

Adrenal incidentaloma: a new cause of the metabolic syndrome?

Terzolo M, Pia A, Alì A, Osella G, Reimondo G, Bovio S, Daffara F, Procopio M, Paccotti P, Borretta G, Angeli A.

J Clin Endocrinol Metab. 2002 Mar;87(3):998-1003.

PMID:
11889151
20.

Mifepristone Treatment of Cushing's Syndrome in a Pediatric Patient.

Banerjee RR, Marina N, Katznelson L, Feldman BJ.

Pediatrics. 2015 Nov;136(5):e1377-81. doi: 10.1542/peds.2015-0684.

Supplemental Content

Support Center